Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

3.0K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
3.0K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

828
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
828
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.8K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity of combinations of bactericidal and bacteriostatic compounds in <i>Mycobacterium abscessus</i>-infected mice: an overview.

Frontiers in microbiology·2025
Same author

Identification of Rv1133c (MetE) as a marker of <i>Mycobacterium tuberculosis</i> replication and as a highly immunogenic antigen with potential immunodiagnostic power.

Frontiers in immunology·2024
Same author

Exploring diagnostic methods for drug-resistant tuberculosis: A comprehensive overview.

Tuberculosis (Edinburgh, Scotland)·2024
Same author

Mycobacterium tuberculosis antigen 85B modifies BCG-induced antituberculosis immunity and favors pathogen survival.

Journal of leukocyte biology·2024
Same author

Eradication of Drug-Tolerant <i>Mycobacterium tuberculosis</i> 2022: Where We Stand.

Microorganisms·2023
Same author

Epidemiology and drug susceptibility of nontuberculous mycobacteria (NTM) in Italy in 2016-2020.

Annali dell'Istituto superiore di sanita·2023

Related Experiment Video

Updated: May 4, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K

Targeting dormant bacilli to fight tuberculosis.

Lanfranco Fattorini1, Giovanni Piccaro1, Alessandro Mustazzolu1

  • 1Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanità, Roma.

Mediterranean Journal of Hematology and Infectious Diseases
|December 24, 2013
PubMed
Summary

Developing new drugs to kill dormant Mycobacterium tuberculosis (Mtb) is crucial for shortening tuberculosis (TB) treatment and reducing the global reservoir of latent TB infections.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
Growth of Mycobacterium tuberculosis Biofilms
09:03

Growth of Mycobacterium tuberculosis Biofilms

Published on: February 15, 2012

23.4K

Related Experiment Videos

Last Updated: May 4, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.1K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K
Growth of Mycobacterium tuberculosis Biofilms
09:03

Growth of Mycobacterium tuberculosis Biofilms

Published on: February 15, 2012

23.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) affects 2 billion people globally, with 10% progressing to active disease from latent infections.
  • Dormant Mtb bacilli can persist for decades in granulomatous lesions, posing a challenge for current treatment regimens.
  • Existing TB therapy requires prolonged treatment durations, highlighting the need for strategies to eliminate dormant bacilli.

Purpose of the Study:

  • To address the critical need for novel drugs and drug combinations effective against dormant Mycobacterium tuberculosis (Mtb) bacilli.
  • To develop strategies for shortening the treatment duration for both active and latent tuberculosis (TB).
  • To reduce the global reservoir of latent TB infections by targeting persistent Mtb.

Main Methods:

  • Focus on identifying drugs with high penetration into caseous granulomas.
  • Investigating the biology of dormant Mtb bacilli, particularly antibiotic-tolerant persister cells.
  • Evaluating novel drugs and combinations against both replicating and non-replicating Mtb in vitro, animal models, and human clinical trials.

Main Results:

  • Unprecedented efforts in TB drug discovery are underway.
  • Novel drugs and drug combinations are being identified to target dormant Mtb.
  • Research is progressing across in vitro, animal model, and human clinical trial settings.

Conclusions:

  • Eliminating dormant Mtb bacilli is essential for eradicating TB and reducing the latent TB reservoir.
  • Understanding persister cell biology and developing drugs that penetrate granulomas are key to successful eradication.
  • Continued investment in TB drug discovery is vital for developing shorter, more effective TB therapies.